EGFR NP_005219.2:p.T790M

Known as: EGFR T790M, Epidermal Growth Factor Receptor T790M, EGFR p.T790M 
A change in the amino acid residue at position 790 in the epidermal growth factor receptor protein where threonine has been replaced by methionine.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Background Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
PURPOSE Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
 
  • figure 1
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR… (More)
  • figure 1
  • table 1
  • table 2
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
UNLABELLED Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
UNLABELLED EGFR-mutant lung cancers responsive to reversible EGFR inhibitors (gefitinib/erlotinib) develop acquired resistance… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PURPOSE Concomitant genetic alterations could account for transient clinical responses to tyrosine kinase inhibitors of the EGF… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?